Non-Viral Gene Delivery with Nanoplasmid™ vector and TcBuster™

Welcome to an Innovation Partnership for Cell & Gene Therapy

Are you ready to revolutionize your research and therapeutic applications? Discover the latest advancements in cell & gene therapy with the Nanoplasmid™ vector system and the TcBuster™ Transposon system, two groundbreaking technologies designed to enhance your scientific endeavors.

Nanoplasmid Vector: The Next Generation of Plasmid DNA

Nanoplasmid vector system offers unparalleled benefits over traditional plasmid DNA:

  • Smaller Size, Greater Performance: Engineered for high expression and reduced immune response.
  • Enhanced Transfection Efficiency: Achieve superior results both in vitro and in vivo studies.
  • Minimized Antibiotic Resistance: Eliminate concerns about antibiotic resistance genes, ensuring a safer, more ethical approach.

Applications

  • Cell Therapy: Deliver therapeutic genes with precision and minimal side effects, potentially with no cargo size limitation.
  • Cell Engineering: Advance your research with robust and reliable gene delivery.
  • Unleash the Power of Transposition
TcBuster System: Transposase mRNA + Nanoplasmid-Based Gene Delivery

TcBuster is a state-of-the-art transposon system that offers:

  • High Integration Efficiency: Achieve stable gene integration with robust expression.
  • Deliver Large Cargo: Insert large, multicistronic cargo with a single Nanoplasmid vector
  • Scale to the Clinic: Ideal for both small-scale experiments and large-scale therapeutic applications.

Applications

  • Immune Cell Therapy Development: Develop groundbreaking treatments with efficient, cost-effective gene insertion.
  • Stable Cell Line Generation: Create cell lines with consistent and reliable gene expression.
  • Stem Cell Editing: Deliver genes to stem cells for research or therapeutic applications.

Therapeutic Development with both Nanoplasmid and TcBuster Systems

Current Success Stories

Oct 2024 - Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy Bridge J, Johnson MJ, Jihyun Kim J, Wenthe S, Joshua Krueger, Bryce Wick, Kluesner M, Andrew T. Crane, Jason Bell, Joseph G. Skeate, Branden S. Moriarity, Beau R. Webber

Aug 2024 - University Hospitals Seidman Cancer Center has initiated a Phase 1 clinical trial for a BAFF CAR T-cell therapy for patients.

Dec 2023 - Luminary Therapeutics has received FDA clearance for its first Investigational New Drug (IND) application to begin a Phase 1 clinical trial of LMY-920, a novel BAFF CAR T-cell therapy designed to treat systemic lupus erythematosus (SLE).

Why Combine Nanoplasmid and TcBuster?

At the forefront of genetic innovation, Aldevron and Bio-Techne are committing these technologies to provide cutting-edge tools that empower researchers and clinicians. Our products are:

The TcBuster platform with transposons built with Nanoplasmid vector system offers exceptional non-viral gene delivery performance:

* E:T ratio of 1:1 or greater, and cell type dependent

Join the Revolution in Cell and Gene Therapy

Embrace the future of cell and gene therapy with Nanoplasmid and TcBuster

Unlock the full potential of your research with Nanoplasmid and TcBuster. Transform your approach to gene delivery and integration and make groundbreaking discoveries that could change the future of medicine.

Read our guide to get your questions answered and learn how to take advantage of the Nanoplasmid and TcBuster systems together.

FAQs and Ordering Information

Resources